Abstract: The present invention provides conjugates of CD70 antibodies, and/or antigen binding portions thereof, for use in the treatment of cancer and autoimmune disease.

Abstract: The present invention provides PTK7 antibodies, antigen binding portions thereof, other binding agents and PTK7 conjugates thereof, as well as methods and uses of such antibodies and conjugates the treatment of cancer and autoimmune disease.

Abstract: The present invention provides Polar units, Linker intermediates, Linkers, Drug-Linkers and Conjugates thereof.

Abstract: The present invention provides Polar units, Linker intermediates, Linkers, Drug-Linkers and Conjugates thereof.

Abstract: The present invention provides Polar units, Linker intermediates, Linkers, Drug-Linkers and Conjugates thereof.

Abstract: The present invention provides Polar units, Linker intermediates, Linkers, Drug-Linkers and Conjugates thereof.

Abstract: Described herein are bispecific binding proteins that specifically bind to an antigen expressed on a target cell and an antigen expressed on a T-cell, e.g., human CD33 and human CD3 and therapeutically effective dosing regimens for the treatment and amelioration of an inflammatory disease and condition.

Abstract: Described herein are bispecific binding proteins that specifically bind to an antigen expressed on a target cell and an antigen expressed on a T-cell, e.g., human CD33 and human CD3 and therapeutically effective dosing regimens for immunotherapy of cancers, diseases and conditions such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and solid tumor cancers.

Abstract: Provided are novel anti-DLL3 antibodies and antibody drug conjugates, and methods of using such anti-DLL3 antibodies and antibody drug conjugates to treat cancer.

Abstract: Methods of optimal dosing of CD19-antibody drug conjugates are disclosed.

Abstract: Provided is a method of determining a mode in a multi-mode terminal. The method includes the steps of: receiving key input of a telephone number; displaying a connectable service mode corresponding to the key input of the telephone number; receiving key input corresponding to the service mode; determining a prefix corresponding to the key input of the service mode; and adding the determined prefix in front of the telephone number to be transmitted, wherein the connectable service mode is automatically renewed in the region where the service is provided. Also, a multi-mode terminal is provided.

Abstract: Provided is a distributed and asynchronous implicit token carrier sense multiple access/collision avoidance (CSMA/CA) protocol guaranteeing quality of service for both real time and non-real time traffic. The implicit token CSMA/CA protocol allocates a band in an entire bandwidth to voice traffic and allows the remaining bands to be used for data traffic. The implicit token CSMA/CA protocol includes applying a token passing protocol to transmit voice traffic in real time by having a band in an entire bandwidth allocated using a predetermined data frame and applying a CSMA/CA mechanism to transmit data traffic in non-real time by employing remaining bands not allocated to the voice traffic using another predetermined data frame.